Hier finden Sie News über unser Unternehmen, unser Geschäft und unsere Produktentwicklungen. 

Sirio Held Communication Meeting on Probiotic Gummies Innovation Technology and Probiotic Market Development

On December 17th and 19th, Sirio gathered academic experts, PhDs in R&D, and market insight experts in the field of probiotics in China and held respective communication meetings in Shanghai and Guangzhou on innovative technologies of probiotic gummies and the development of probiotic markets.

Sirio’s SAP ERP on-line to bolster IT strength

On December 2, Sirio Pharma formally launched the SAP ERP system that covers seven facets of its business operation, namely, finance, procurement, production, sales, warehouse management, customer service, and quality management.

Sirio Pharma and Kerry Group Form Ground-Breaking Agreement for Probiotic Gummies

Asia, Europe & The United States, 17 November, 2019: Sirio Pharma (300791) announces the signing of Probiotic Strategy Cooperation Agreement (BC30) with the Kerry Group. The collaboration was confirmed at Sirio’s China Research and Development Center in Shantou, Guangdong and is expected to harness the huge growth opportunity in China’s emerging probiotic gummy sector.

Sailing Together, in Pursuit of Health and Wellness SIRIO Inscribed in A-share Market

At the sound of the listing bell of the Shenzhen Stock Exchange on September 25, 2019, SIRIO Pharma Co. Ltd(share code: 300791)is officially listed on the A-share Market with an opening price of RMB 54.73 and closing price at RMB 76.60, an immediate increase of 39.96%.

Sirio schließt Akquisitionen des bekannten Softgelhersteller Herstellers Ayanda ab

Sirio Pharma Co., Ltd (SIRIO) gibt heute bekannt, dass SIRIO die Ayanda GmbH & Co. KG (Ayanda), einen bekannten Softgelhersteller in Europa, übernommen hat. Ayanda ist nun eine hundertprozentige Gesellschaft von SIRIO.